Cutaneous T-cell lymphoma (CTCL)

Indication for Bexarotene

Population group: Suitable for both men and women, only adults (18 years old or older)

Bexarotene is indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) in adult patients refractory to at least one systemic treatment.

For this indication, competent medicine agencies globally authorize below treatments:

300 mg/m² once daily

Route of admnistration


Defined daily dose

300 - 300 mg per m² of body surface area (BSA)

Dosage regimen

From 300 To 300 mg per m² of body surface area (BSA) once every day

Detailed description

The recommended initial dose is 300 mg/m²/day. Initial dose calculations according to body surface area are as follows:

Recommended initial dose:

Initial dose level (300 mg/m²/ημέρα)Number of 75 mg bexarotene capsules
Body Surface Area (m²)Total daily dose (mg/ημέρα)0.88–1.123004

Dose modification guidelines

The 300 mg/m²/day dose level may be adjusted to 200 mg/m²/day then to 100 mg/m²/day, or temporarily suspended, if necessitated by toxicity. When toxicity is controlled, doses may be carefully readjusted upward. With appropriate clinical monitoring, individual patients may benefit from doses above 300 mg/m²/day. Doses greater than 650 mg/m²/day have not been evaluated in patients with CTCL. In clinical trials, bexarotene was administered for up to 118 weeks to patients with CTCL. Treatment should be continued as long as the patient is deriving benefit.

Active ingredient

Bexarotene is a synthetic compound that exerts its biological action through selective binding and activation of the three RXRs: α, β, and γ. Once activated, these receptors function as transcription factors that regulate processes such as cellular differentiation and proliferation, apoptosis, and insulin sensitisation. The exact mechanism of action of bexarotene in the treatment of cutaneous T-cell lymphoma (CTCL) is unknown.

Read more about Bexarotene

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner